Literature DB >> 24866179

Myeloid lineage-specific deletion of antioxidant system enhances tumor metastasis.

Keiichiro Hiramoto1, Hironori Satoh2, Takafumi Suzuki3, Takashi Moriguchi2, Jingbo Pi4, Tooru Shimosegawa5, Masayuki Yamamoto3.   

Abstract

Oxidative stress accelerates the pathogenesis of a number of chronic diseases including cancer growth and its metastasis. Transcription factor NF-E2-related factor-2 (Nrf2), which regulates the cellular defense system against oxidative stress, elicits essential protection against chemical-induced carcinogenic insults. We recently demonstrate that the systemic deletion of Nrf2 leads to an increased susceptibility to cancer metastasis, which is associated with aberrant reactive oxygen species (ROS) accumulation in myeloid-derived suppressor cells (MDSC). However, it remains elusive whether cellular antioxidant defense system in the myeloid lineage cells plays indispensable roles for metastatic cancer progression. We herein found that myeloid lineage-specific Nrf2-deficient mice exhibited an increased susceptibility to pulmonary metastasis of the mouse Lewis lung carcinoma cells, and ROS level was more highly elevated in MDSCs of cancer-bearing Nrf2-deficient mice. Similarly, myeloid lineage-specific deletion of selenocysteine-tRNA gene (Trsp), which is essential for synthesis of antioxidant selenoenzymes, resulted in increased number of metastatic nodules along with ROS accumulation in MDSCs of cancer-bearing mice. These results thus indicate that the antioxidant systems directed by Nrf2 and selenoenzymes contribute to the clearance of ROS in MDSCs, efficiently preventing cancer cell metastasis. Consistent with this notion, a synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl] imidazole (CDDO-Im), a potent Nrf2 inducer, attenuated the ROS production in MDSCs, and thereafter reduced metastatic nodules. Taken together, this study provides compelling lines of evidence that Nrf2 inducer retains therapeutic efficacy against cancer cell metastasis. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24866179     DOI: 10.1158/1940-6207.CAPR-14-0094

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  43 in total

Review 1.  NRF2 and the Hallmarks of Cancer.

Authors:  Montserrat Rojo de la Vega; Eli Chapman; Donna D Zhang
Journal:  Cancer Cell       Date:  2018-05-03       Impact factor: 31.743

2.  Nrf2 prevents Notch-induced insulin resistance and tumorigenesis in mice.

Authors:  Dionysios V Chartoumpekis; Yoko Yagishita; Marco Fazzari; Dushani L Palliyaguru; Uma Nm Rao; Apostolos Zaravinos; Nicholas Kh Khoo; Francisco J Schopfer; Kurt R Weiss; George K Michalopoulos; Ian Sipula; Robert M O'Doherty; Thomas W Kensler; Nobunao Wakabayashi
Journal:  JCI Insight       Date:  2018-03-08

3.  Cellular Nrf2 Levels Determine Cell Fate during Chemical Carcinogenesis in Esophageal Epithelium.

Authors:  Makoto Horiuchi; Keiko Taguchi; Wataru Hirose; Kouhei Tsuchida; Mikiko Suzuki; Yusuke Taniyama; Takashi Kamei; Masayuki Yamamoto
Journal:  Mol Cell Biol       Date:  2021-01-25       Impact factor: 4.272

4.  Absolute Amounts and Status of the Nrf2-Keap1-Cul3 Complex within Cells.

Authors:  Tatsuro Iso; Takafumi Suzuki; Liam Baird; Masayuki Yamamoto
Journal:  Mol Cell Biol       Date:  2016-11-28       Impact factor: 4.272

5.  The effects of NRF2 modulation on the initiation and progression of chemically and genetically induced lung cancer.

Authors:  Shasha Tao; Montserrat Rojo de la Vega; Eli Chapman; Aikseng Ooi; Donna D Zhang
Journal:  Mol Carcinog       Date:  2017-11-06       Impact factor: 4.784

6.  Nrf2 Activation Promotes Lung Cancer Metastasis by Inhibiting the Degradation of Bach1.

Authors:  Luca Lignitto; Sarah E LeBoeuf; Harrison Homer; Shaowen Jiang; Manor Askenazi; Triantafyllia R Karakousi; Harvey I Pass; Arjun J Bhutkar; Aristotelis Tsirigos; Beatrix Ueberheide; Volkan I Sayin; Thales Papagiannakopoulos; Michele Pagano
Journal:  Cell       Date:  2019-06-27       Impact factor: 41.582

7.  NRF2: KEAPing Tumors Protected.

Authors:  Ray Pillai; Makiko Hayashi; Anastasia-Maria Zavitsanou; Thales Papagiannakopoulos
Journal:  Cancer Discov       Date:  2022-03-01       Impact factor: 38.272

8.  RTA 408, A Novel Synthetic Triterpenoid with Broad Anticancer and Anti-Inflammatory Activity.

Authors:  Brandon L Probst; Isaac Trevino; Lyndsey McCauley; Ron Bumeister; Irina Dulubova; W Christian Wigley; Deborah A Ferguson
Journal:  PLoS One       Date:  2015-04-21       Impact factor: 3.240

9.  Cancer Cell Growth Is Differentially Affected by Constitutive Activation of NRF2 by KEAP1 Deletion and Pharmacological Activation of NRF2 by the Synthetic Triterpenoid, RTA 405.

Authors:  Brandon L Probst; Lyndsey McCauley; Isaac Trevino; W Christian Wigley; Deborah A Ferguson
Journal:  PLoS One       Date:  2015-08-24       Impact factor: 3.240

10.  Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription.

Authors:  Eri H Kobayashi; Takafumi Suzuki; Ryo Funayama; Takeshi Nagashima; Makiko Hayashi; Hiroki Sekine; Nobuyuki Tanaka; Takashi Moriguchi; Hozumi Motohashi; Keiko Nakayama; Masayuki Yamamoto
Journal:  Nat Commun       Date:  2016-05-23       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.